Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
About
SciClone Pharmaceuticals, Inc. is a global biopharmaceutical company. The Company acquires, develops, and commercializes drugs for treating chronic and life-threatening diseases such as cancer, hepatitis B, hepatitis C, cystic fibrosis, and immune system disorders.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E.
Data is available to registered users only
Buy
Sell